Healthy Returns: Biotech IPOs ramped up to start 2024, but the market hasn't fully recovered just yet [CNBC]
Kyverna Therapeutics, Inc. (KYTX)
Company Research
Source: CNBC
After a two-year dry spell, initial public offerings by biotech companies showed signs of life during the first three months of 2024. But it's too early to say that the biotech IPO market has fully recovered. Biotech IPOs appeared to reach pre-pandemic levels during the first quarter, with nine companies collectively raising more than $1.3 billion, according to a database from BioPharma Dive. That is more than three times the roughly $375 million raised from biotech IPOs in the first quarter of 2023. Here are the companies that went public in the first quarter of 2024, according to the BioPharma Dive database: – 1/24, raised $380 million – 1/25, raised $175 million – 2/1, raised $129 million – 2/1, raised $110 million – 2/7, raised $319 million – 2/8, raised $7 million – 2/8, raised $94 million – 2/15, raised $7 million – 3/27, raised $100 million Another company, Contineum Therapeutics , went public on April 4 and raised $110 million. Six of the nine IPOs
Show less
Read more
Impact Snapshot
Event Time:
KYTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYTX alerts
High impacting Kyverna Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYTX
News
- Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsPR Newswire
- Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases [Yahoo! Finance]Yahoo! Finance
- Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune DiseasesPR Newswire
- ViroCell to present at 2024 Cell & Gene Meeting on the Med [Yahoo! Finance]Yahoo! Finance
- First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med [Yahoo! Finance]Yahoo! Finance
KYTX
Sec Filings
- 5/14/24 - Form 10-Q
- 5/14/24 - Form 8-K
- 5/3/24 - Form SC
- KYTX's page on the SEC website